| 10.55 0.79 (8.09%) | 05-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 12.54 | 1-year : | 14.65 |
| Resists | First : | 10.73 | Second : | 12.54 |
| Pivot price | 9.74 |
|||
| Supports | First : | 8.33 |
Second : | 6.84 |
| MAs | MA(5) : | 10.01 |
MA(20) : | 9.5 |
| MA(100) : | 8.21 |
MA(250) : | 0 | |
| MACD | MACD : | 0.5 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 71.7 |
D(3) : | 67.1  |
| RSI | RSI(14): 64.5 |
|||
| 52-week | High : | 11.72 | Low : | 5.51 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ACTU ] has closed below upper band by 10.2%. Bollinger Bands are 9.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.7 - 10.74 | 10.74 - 10.79 |
| Low: | 9.69 - 9.73 | 9.73 - 9.78 |
| Close: | 10.47 - 10.55 | 10.55 - 10.62 |
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
Tue, 06 May 2025
Actuate Therapeutics Announces Positive Phase 2 Trial Results - TipRanks
Tue, 06 May 2025
Actuate stock jumps after cancer trial data (ACTU:NASDAQ) - Seeking Alpha
Tue, 06 May 2025
Actuate Therapeutics Reports Positive Data From Phase 2 Study Of Elraglusib In Pancreatic Cancer - Nasdaq
Wed, 30 Apr 2025
Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025 - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 20 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 19 (%) |
| Held by Institutions | 52.4 (%) |
| Shares Short | 137 (K) |
| Shares Short P.Month | 93 (K) |
| EPS | -3.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -255.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -22 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -3.24 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|